Markets

Positive Data on Novartis' LDE225 - Analyst Blog

A close up of a screen.
Credit: Shutterstock photo

Novartis ( NVS ) announced positive results from a phase II trial, BOLT (Basal cell carcinoma Outcomes in LDE225 Trial), on pipeline candidate LDE225 (sonidegib) at the American Society of Clinical Oncology (ASCO).

Novartis is evaluating the candidate for the treatment of patients suffering from locally advanced basal cell carcinoma (laBCC) or metastatic basal cell carcinoma (mBCC).

The results of the study showed that LDE225 showed sustained tumor shrinkage after a median follow-up of 13.9 months.

The phase II trial assessed the efficacy and safety of two oral doses of LDE225 in patients suffering from laBCC or mBCC. The primary endpoint was the objective response rate (ORR) which indicates proportion of patients with complete or partial tumor response or shrinkage, as measured by a central review committee. The study met its primary endpoint.

Novartis expects the positive data from the phase II trial to serve as the basis for worldwide regulatory filings for LDE225 for the treatment of advanced basal cell carcinoma later in 2014.

The successful development and commercialization of LDE225 will further strengthen Novartis' strong oncology portfolio.

Meanwhile, we cautiously watch Novartis' efforts to realign its portfolio in order to focus on its core business of pharmaceuticals, eye care and generics. We believe the recent acquisition of oncology products from GlaxoSmithKline ( GSK ) and divestment of Vaccines business is a step in the right direction.

Novartis also entered into a definitive agreement with Eli Lilly and Co . ( LLY ) to divest the Animal Health Division.

We are positive on Novartis' efforts to transform its portfolio. We remind investors that Novartis divested its blood transfusion diagnostics unit to Grifols S.A. for approximately $1.7 billion in cash in Jan 2014.

The acquisition of oncology products from GlaxoSmithKline and divestment of Vaccines business is a step in the right direction. It will broaden Novartis' portfolio and enable it to focus better on its core capabilities besides contributing immensely to the top line. Margins are also expected to get a significant boost.

Novartis currently carries a Zacks Rank #3 (Hold). Investors looking for better-ranked stocks may consider companies like Allergan ( AGN ) with a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

LILLY ELI & CO (LLY): Free Stock Analysis Report

ALLERGAN INC (AGN): Free Stock Analysis Report

GLAXOSMITHKLINE (GSK): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GSK LLY NVS

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More